<DOC>
	<DOCNO>NCT01820247</DOCNO>
	<brief_summary>The purpose study assess effect Tripterygium Glycosides Combined enteral nutrition treatment Crohn 's disease induction remission compare therapeutic effect patient receive Tripterygium Glycosides enteral nutrition .</brief_summary>
	<brief_title>Efficacy Study Tripterygium Glycoside Combined With Enteral Nutrition Treatment Crohn 's Disease Induction Remission</brief_title>
	<detailed_description>Crohn 's disease characterize inflammation ulceration small intestine colon . Patients commonly experience abdominal pain , diarrhea，malnutrition malaise result decrease quality life increase risk chronic disability unemployment . Tripterygium Glycosides ( T2 ) chloroform/methanol extract Tripterygium wilfordii Hook F ( TWHF ) , traditional Chinese medicine , use rheumatoid arthritis nephritis . It immunomodulatory anti-inflammatory activities.Our previous animal study reveal major component T2 , triptolide , could prevent development chronic colitis interleukin-10 deficient mouse . The phase I clinical trial institute also demonstrate T2 , combine enteral nutrition , efficient induction remission patient active Crohn 's disease.The common adverse effect T2 leucopenia , liver renal toxicity , oligospermia amenorrhea . The purpose study assess effect Tripterygium Glycosides Combined enteral nutrition treatment Crohn 's disease induction remission compare therapeutic effect patient receive Tripterygium Glycosides enteral nutrition .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Cardiac Glycosides</mesh_term>
	<criteria>Subjects definitive diagnosis Crohn 's disease , base WHO criteria Males female ≥ 18 year old , include woman pregnant lactating time enrollment . Subjects CDAI score ≥ 150 week 0 Able swallow tablet Are capable provide write informed consent obtain time enrollment Willing adhere study visit schedule protocol requirement . Bacterial , viral microbial infection ( include HIV ) Needing orally administer corticosteroid treatment disease . Inhaled dermatologic preparation acceptable . Previous current use infliximab . current use prescription dos chronic/frequent use NSAIDs Treatment narcotic pain medication . ( Antidiarrheal agent loperamide diphenoxylate permit ) History pancreatitis , except subject know remove cause ( gallstone pancreatitis ) History abnormal liver function test , include AST ALT &gt; 1.5 time upper limit normal , alkaline phosphatase &gt; 2 time upper limit normal , total bilirubin &gt; 2.5 mg/dL screening ( within previous 6 month , know ) History malignancy Women pregnant lactating time enrollment , intend study period . Participation clinical trial within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>enteral nutrition</keyword>
	<keyword>Tripterygium Glycosides</keyword>
	<keyword>induction remission</keyword>
</DOC>